目的：探讨t(8;2 1)对儿童AML -M2 的疗效和预后的影响。方法：对14例有t(8;2 1)和 2 1例无t(8;2 1)的M2 患儿的临床特征、疗效、复发率、死亡率及无病生存率进行分析。结果：14例t(8;2 1)和 2 1例无t(8;2 1)的M2 患儿在年龄、白细胞数等临床特征上的差异无统计意义 (P >0 .0 5 )。t(8;2 1)组的完全缓解 (CR)率明显高于无t(8;2 1)组 (92 .9%vs 5 7.1% ) (P <0 .0 5 ) ,而两组的复发率和死亡率差异无显著性 (P >0 .0 5 )。总的无事生存率t(8;2 1)组低于无t(8;2 1)组 (6 9.2 %vs 77.8% ) (P <0 .0 5 )。结论：t(8;2 1)的儿童M2 并不一定具有良好的预后。t(8;2 1)对M2 预后的影响可能存在人种及地区的差异。

OBJECTIVE: To study the influence of t(8;21) on the curative effect and prognosis of children with acute myelocytic leukemia M 2 (AML M 2). METHODS:The clinical characteristics, curative effects, relapse rate, mortality and event free survival (EFS) rate of 14 cases of M 2 children with t(8;21) and 21 cases of M 2 children without t(8;21) were analysed. RESULTS: There was no statistical difference in age, initial WBC count and clinical characteristics between the M 2 patients with t(8;21) and without t(8;21)(P> 0.05 ). The complete remission rate ( 92.9% ) in M 2 patients with t(8;21) was significantly higher than that ( 57.1% ) of children without t(8;21) (P< 0.05 ), while the relapse rate and mortality were of no marked difference between the two groups (P> 0.05 ). The overall EFS rate in M 2 children with t(8;21) was lower ( 69.2% ) than that ( 77.8% ) of children without t(8;21) (P< 0.05 ). CONCLUSIONS: The prognosis of the M 2 children with t(8;21) was not better than that of the M 2 children without t(8;21). The infuence of t(8;21) on the prognosis of M 2 might be different from race and region.